{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:30:50Z","timestamp":1780918250686,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/23864-7"],"award-info":[{"award-number":["2019\/23864-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/12909-7"],"award-info":[{"award-number":["2020\/12909-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/01460-1"],"award-info":[{"award-number":["2021\/01460-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/11606-3"],"award-info":[{"award-number":["2021\/11606-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.lfs.2022.121146","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T12:14:57Z","timestamp":1667477697000},"page":"121146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"PB","title":["Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"311","author":[{"given":"Jean Carlos","family":"Lipreri da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Saldanha-Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael Costa Bandeira","family":"de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Passos","family":"Vicari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandda Evelin","family":"Silva-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Buccheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2022.121146_bb0005","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2022.121146_bb0010","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lfs.2022.121146_bb0015","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3960\/jslrt.20036","article-title":"Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies","volume":"60","author":"Kikushige","year":"2020","journal-title":"J. Clin. Exp. Hematopathol."},{"key":"10.1016\/j.lfs.2022.121146_bb0020","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukemia","volume":"391","author":"Hallek","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2022.121146_bb0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-021-01054-w","article-title":"Current and future treatment strategies in chronic lymphocytic leukemia","volume":"14","author":"Patel","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2022.121146_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000510768","article-title":"Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs","volume":"144","author":"Smolewski","year":"2021","journal-title":"Acta Haematol."},{"key":"10.1016\/j.lfs.2022.121146_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061336","article-title":"Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance","volume":"13","author":"Furstenau","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2022.121146_bb0040","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/leu.2015.86","article-title":"Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma","volume":"29","author":"Pore","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2022.121146_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevImmunol.2015012327","article-title":"The ezrin-radixin-moesin family of proteins in the regulation of B-cell immune response","volume":"35","author":"Pore","year":"2015","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.lfs.2022.121146_bb0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrm2866","article-title":"Organizing the cell cortex: the role of ERM proteins","volume":"11","author":"Fehon","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.lfs.2022.121146_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188753","article-title":"Ezrin gone rogue in cancer progression and metastasis: an enticing therapeutic target","volume":"1877","author":"Barik","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.lfs.2022.121146_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.588801","article-title":"Ezrin mediates invasion and metastasis in tumorigenesis: a review","volume":"8","author":"Song","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.lfs.2022.121146_bb0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.lfs.2022.121146_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1875036201004010005","article-title":"Amazonia!: an online resource to Google and visualize public human whole genome expression data","volume":"4","author":"Carrour","year":"2010","journal-title":"Open Bioinforma.J."},{"key":"10.1016\/j.lfs.2022.121146_bb0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2022.121146_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.lfs.2022.121146_bb0085","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lfs.2022.121146_bb0090","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2022.121146_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-021-00436-0","article-title":"The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action","volume":"11","author":"Chen","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.lfs.2022.121146_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/onc.2011.245","article-title":"Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells","volume":"31","author":"Bulut","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.lfs.2022.121146_bb0105","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s13402-021-00621-0","article-title":"Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia","volume":"44","author":"Lipreri da Silva","year":"2021","journal-title":"Cell Oncol."},{"key":"10.1016\/j.lfs.2022.121146_bb0110","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14728222.2020.1832465","article-title":"Targeting p53 in chronic lymphocytic leukemia","volume":"24","author":"Moia","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.lfs.2022.121146_bb0115","first-page":"123","article-title":"PI3K signaling in Normal B cells and chronic lymphocytic leukemia(CLL)","volume":"393","author":"Okkenhaug","year":"2016","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.lfs.2022.121146_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061280","article-title":"Lessons, challenges and future therapeutic opportunities for PI3K inhibition in CLL","volume":"13","author":"Guarente","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lfs.2022.121146_bb0125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219","article-title":"The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia","volume":"100","author":"Ferrajoli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lfs.2022.121146_bb0130","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/s41375-019-0444-6","article-title":"KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival","volume":"33","author":"Vendramini","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.lfs.2022.121146_bb0135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Gimenez","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.lfs.2022.121146_bb0140","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1074\/jbc.M116.718189","article-title":"Ezrin inhibition up-regulates stress response gene expression","volume":"291","author":"Celik","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.lfs.2022.121146_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neo.2016.01.002","article-title":"Ezrin enhances EGFR signaling and modulates erlotinib sensitivity in non-small cell lung cancer cells","volume":"18","author":"Saygideger-Kont","year":"2016","journal-title":"Neoplasia"},{"key":"10.1016\/j.lfs.2022.121146_bb0150","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-018-1079-7","article-title":"Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer","volume":"21","author":"Ghaffari","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2022.121146_bb0155","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s10637-022-01249-z","article-title":"NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells","volume":"40","author":"Lipreri da Silva","year":"2022","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.lfs.2022.121146_bb0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(98)00154-4","article-title":"MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation","volume":"23","author":"Stacchini","year":"1999","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lfs.2022.121146_bb0165","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/092986708783503212","article-title":"From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage","volume":"15","author":"Petrelli","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.lfs.2022.121146_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.lfs.2022.121146_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9070633","article-title":"Targeting the MAPK\/ERK and PI3K\/AKT signaling pathways affects NRF2, Trx and GSH antioxidant systems in leukemia cells","volume":"9","author":"Jasek-Gajda","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.lfs.2022.121146_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188716","article-title":"Cyclin-dependent kinases in DNA damage response","volume":"1877","author":"Kciuk","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.lfs.2022.121146_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.seminoncol.2016.02.003","article-title":"Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia","volume":"43","author":"Blachly","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lfs.2022.121146_bb0190","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2022.121146_bb0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-021-00862-z","article-title":"BCL-2 inhibition as treatment for chronic lymphocytic leukemia","volume":"22","author":"Perini","year":"2021","journal-title":"Curr. Treat. OptionsOncol."},{"key":"10.1016\/j.lfs.2022.121146_bb0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/bjh.13042","article-title":"A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53","volume":"167","author":"Shindiapina","year":"2014","journal-title":"Br. J. Haematol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522008463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:02:32Z","timestamp":1758402152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522008463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S0024320522008463"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121146","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.121146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"121146"}}